Triplixam Contraindications

Dialysis patients; Patients with untreated decompensated heart failure; Severe renal impairment (creatinine clearance below 30 mL/min); Moderate renal impairment (creatinine clearance below 60 mL/min) for Triplixam doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg); Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients listed in Description; History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy (see Warnings); Hereditary/idiopathic angioedema; Second and third trimesters of pregnancy (see Warnings and Use in Pregnancy & Lactation); Lactation (see Use in Pregnancy & Lactation); Hepatic encephalopathy; Severe hepatic impairment; Hypokalaemia; Severe hypotension; Shock, including cardiogenic shock; Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis); Haemodynamically unstable heart failure after acute myocardial infarction; Concomitant use of Triplixam with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m²) (See Interactions and Pharmacology: Pharmacodynamics under Actions); Concomitant use with sacubitril/valsartan (see Warnings and Interactions); Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see Interactions); Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see Warnings and Precautions).